Yet, despite these potential liabilities, BCL11A has become the leading therapeutic target for sickle cell disease due to the magnitude of HbF induction upon BCL11A perturbation, genetic engineering advances45–47, and discovery of BCL11A’s erythroid-specific enhancer48. The gene discussed is BCL11A; the disease is sickle cell disease.